Presentation is loading. Please wait.

Presentation is loading. Please wait.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Published byAlfhild Nordli Modified over 5 years ago

Similar presentations

Presentation on theme: "Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and."— Presentation transcript:

1 Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis  Robert Bissonnette, MD, David M. Pariser, MD, Norman R. Wasel, MD, FRCPC, Joana Goncalves, MD, Robert M. Day, PhD, Rongdean Chen, PhD, Michael Sebastian, MD  Journal of the American Academy of Dermatology  Volume 75, Issue 1, Pages (July 2016) DOI: /j.jaad Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Patient disposition for the PSOR-005, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1, and ESTEEM 2 clinical studies. PPPGA, Palmoplantar Psoriasis Physician Global Assessment. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Achievement of Palmoplantar Psoriasis Physician Global Assessment (PPPGA) score of 0 (clear) or 1 (almost clear) at week 16 in patients with a PPPGA score 3 or higher at baseline, indicating moderate or severe palmoplantar psoriasis. Missing values were handled using nonresponder imputation. n/N, number of patients with response/sufficient data for evaluation. *P = .021 by Fisher exact test versus placebo. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Effect of apremilast 30 mg twice daily in a patient with palmoplantar psoriasis at baseline (Palmoplantar Psoriasis Physician Global Assessment [PPPGA] score = 3) (A) and week 16 (PPPGA score = 0) (B). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Achievement of Palmoplantar Psoriasis Physician Global Assessment (PPPGA) score of 0 (clear) at week 16 in patients with a PPPGA score 1 or higher at baseline, indicating the presence of any palmoplantar psoriasis. *P < .001 by Fisher exact test versus placebo. BID, Twice a day. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

6 Fig 5 Achievement of Palmoplantar Psoriasis Physician Global Assessment (PPPGA) score of 0 (clear) or 1 (almost clear) with 1-point or more improvement at week 16 in patients with a PPPGA score 1 or higher at baseline, indicating the presence of any palmoplantar psoriasis. *P < .001 by Fisher exact test versus placebo. BID, Twice a day. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and."

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.
Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients  Patrizia Weber, MD, S. Morteza Seyed Jafari,

Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients  Patrizia Weber, MD, S. Morteza Seyed Jafari,
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients  Noël Emile Célestin.

Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients  Noël Emile Célestin.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
Pharmacy costs of specialty medications for plaque psoriasis in the United States  Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Pharmacy costs of specialty medications for plaque psoriasis in the United States  Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis  Lorinda Chung, MD, David Fiorentino,

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis  Lorinda Chung, MD, David Fiorentino,

Similar presentations

Ads by Google